EXAS Stock Risk & Deep Value Analysis
Exact Sciences Corp
Healthcare • Diagnostics & Research
DVR Score
out of 10
The Bottom Line on EXAS
We analyzed Exact Sciences Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran EXAS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
EXAS Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
About Exact Sciences Corp (EXAS)
Sector
Healthcare
Industry
Diagnostics & Research
Market Cap Category
large
Market Cap
$16.11B
EXAS Deep Value Analysis
Compare EXAS to Similar Stocks
See how Exact Sciences Corp stacks up against related companies in our head-to-head analysis.
EXAS Red Flags & Warning Signs
- âš
Negative or inconclusive results from ongoing MCED clinical trials
- âš
Increased competitive pressure or new market entrants in colorectal cancer screening
- âš
Slower-than-anticipated regulatory approvals or reimbursement decisions for new tests
- âš
Broader economic downturn impacting healthcare spending
Unlock EXAS Red Flags & Risk Warnings
Create a free account to see the full analysis
EXAS Financial Health Metrics
Market Cap
$16.11B
EXAS Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
4 Identified
Cologuard's moat is durable due to extensive clinical data, established reimbursement, and high physician adoption rates, creating significant switching costs for healthcare providers. The emerging moat for MCED relies on proprietary technology, clinical validation, and the ability to scale rapidly, which is still developing.
EXAS Competitive Moat Analysis
Sign up to see competitive advantages
EXAS Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated Feb 2026)
- •Updates on Cologuard 2.0 (next-gen) development and commercialization plan
- •Expansion of OncoExTra pan-cancer therapy selection test
Medium-Term (6-18 months)
- •Further clinical data readouts from BLUE-C study for MCED
- •Potential FDA submission for a specific multi-cancer early detection test or next-generation Cologuard
- •Progress on reimbursement coverage for new diagnostic tests
Long-Term (18+ months)
- •Broad commercialization and widespread adoption of the MCED platform
- •Significant international market expansion for core products and MCED
- •Diversification of the cancer diagnostics pipeline beyond current offerings
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
EXAS Bull Case: What Could Go Right
- ✓
Positive clinical trial readouts and accelerated regulatory pathways for MCED candidates (e.g., BLUE-C study data, FDA approvals)
- ✓
Increased Cologuard test volumes and expanding market penetration (especially in new age groups or geographies)
- ✓
Significant improvements in gross margins and progression towards sustainable profitability for the overall business
- ✓
Competitive landscape shifts, particularly any major advancements or setbacks for key MCED rivals
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
